Nieuws

Investing.com8u
BofA verlaagt koersdoel Novavax naar $ 10 van $ 12
Op donderdag heeft BofA Securities-analist Alec Stranahan het koersdoel voor het aandeel Novavax verlaagd naar $ 10,00 van de eerdere $ 12,00, met behoud van een Neutraal advies. De herziening volgt o ...
Investing.com10u
Novavax-aandeel stort in na uitspraken van Amerikaanse gezondheidsminister
Investing.com -- Het aandeel Novavax (NASDAQ: NVAX) kelderde met 24% na uitspraken van de Amerikaanse minister van Volksgezondheid Robert F. Kennedy Jr., die een verschuiving in de prioriteiten van de ...
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...
Anti-vaccine sentiment may derail vaccines already awaiting FDA approval, experts fear
Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...
FDA delays full approval of Novavax Covid-19 vaccine even though it was on track for clearance
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
Fierce Pharma7d
Amid FDA tumult, agency misses decision deadline on Novavax's COVID shot
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
Novavax slides after RFK Jr. casts doubts about COVID vaccine
Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.
Novavax’s Covid vaccine delayed in FDA review
Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine (UPDATED)
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request ...
FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Novavax price target lowered to $10 from $12 at BofA
BofA lowered the firm’s price target on Novavax (NVAX) to $10 from $12 and keeps a Neutral rating on the shares. Shares are sliding over 21% ...